The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Using genomics to understand ibrutinib resistance in Waldenström’s macroglobulinemia
Zachary Hunter, PhD, Dana-Farber Cancer Institute, Boston, MA, speaks about the use of genomic data to understand ibrutinib resistance in Waldenström’s macroglobulinemia. This can be used to predict which patients will respond and for how long. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
